Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.9300
-0.0452 (-4.63%)
Nov 16, 2026, 9:45 AM EST - Market open

Decoy Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.54----1.84
Revenue Growth
------64.84%
Gross Profit
0.54-----6.71
Operating Income
-8.22-4.1-5.73-12.89-22.98-12.81
Net Income
-16.56-12.52-5.58-12.54-31.61-12.77
Earnings Per Share
-29.61-129.10-69.54---
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.1710.712.435.912.1129.21
Total Debt
--0.220.29--
Net Cash (Debt)
8.1710.712.215.6112.1129.21
Net Cash Growth
69.83%384.03%-60.56%-53.66%-58.56%174.53%
Net Cash Per Share
14.60110.4527.59---

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9.27-4.83-4.53-12.85-17.6-10.2
Capital Expenditures
-0.12-----
Free Cash Flow
-9.39-4.83-4.53-12.85-17.6-10.2
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%-----
Operating Margin
-1535.69%-----696.27%
Pretax Margin
-3095.72%-----693.84%
Profit Margin
-3095.72%-----693.84%
FCF Margin
-1754.53%-----554.29%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
1.19----12.17